Biogen Inc.

Valuation Analysis

About the Company

Biogen Inc. en bref

Biogen Inc. (BIIB) is currently trading at 171,55 € with a market capitalization of 25,3 Md €. The trailing P/E ratio stands at 21.16x, with a forward P/E of 11.78x. The 52-week range spans from 105,64 € to 179,75 €; the current price is 4.6% below the yearly high. Year-over-year revenue growth stands at +1.9%. The net profit margin stands at 13.8%.

💰 Dividende

Biogen Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

30 analystes évaluent Biogen Inc. (BIIB) au consensus : Acheter. L'objectif de cours moyen est de 192,10 €, soit un potentiel de +11.98% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 130,90 € à 261,80 €.

Biogen Inc. : la thèse d'investissement en détail

Biogen Inc. (BIIB) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 31.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 78.72%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Revenue growth has slowed to just 1.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valorisation en contexte

At a PEG of 3.94, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 8.8x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 11.78x is meaningfully below the trailing 21.16x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Biogen Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.